查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006161

家庭藥物濫用檢測市場：按分銷管道、檢測類型、檢體類型、技術和最終用戶分類－2026-2032年全球市場預測

At-home Drug of Abuse Testing Market by Distribution Channel, Test Type, Sample Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，家庭藥物濫用檢測市場價值將達到 31 億美元，到 2026 年將成長到 33.3 億美元，到 2032 年將達到 51.1 億美元，複合年成長率為 7.40%。

主要市場統計數據
基準年 2025 31億美元
預計年份：2026年 33.3億美元
預測年份：2032年 51.1億美元
複合年成長率 (%) 7.40%

簡要概述消費者需求、臨床需求和技術進步如何重新定義家庭用藥濫用檢測的標準和期望。

家用藥物濫用檢測領域已從滿足消費者便利的小眾需求發展成為公共衛生、職業安全和臨床管道中的策略要素。消費者如今期望獲得快速可靠的檢測方案，既能保護隱私又能保證臨床級別的準確性；而臨床醫生和雇主則需要能夠整合確認性檢測流程並符合監管要求的解決方案。檢測設計、數位化連接和分散式醫療模式的進步，正在拓展這些檢測的應用範圍，使其從照護現場篩檢到遠端監測和遠端保健干預。

對改變家庭藥物檢測的檢驗、提供和整合到臨床路徑中的結構和技術變革進行詳細考察。

技術突破、監管挑戰以及相關人員優先事項的轉變，正共同推動家用藥物檢測領域發生重大變革。照護現場免疫檢測和側向層析分析儀透過簡化工作流程和加快結果出具速度，顯著提升了使用者體驗。同時，數位化側向層析分析儀實現了自動讀數和安全資料傳輸，減少了使用者誤判，並促進了遠端確認流程。同時，層析法確認仍是分析領域的黃金標準，強化了將居家篩檢與檢查室確認結合的混合檢測管道。

對 2025 年將實施的累積關稅措施如何重塑整個全球家庭檢測價值鏈的採購、製造、定價和分銷策略進行分析評估。

2025年實施的累積關稅措施帶來了新的成本和採購趨勢，影響整個家用藥物檢測領域的製造商、經銷商和零售通路。某些零件和成品進口關稅的提高擠壓了毛利率，迫使製造商重新評估其供應商組合，並尋求替代方案以降低關稅波動帶來的風險。因此，許多公司優先考慮供應商多元化，尋求從關稅影響範圍之外的國家採購零件，並談判長期合約以穩定投入價格。

將分銷管道、測試方法、檢體類型、分析技術和最終用戶需求與商業化要求和產品設計方案進行詳細的細分分析。

關鍵的細分洞察揭示了分銷管道、測試方法、檢體類型、分析技術和最終用戶等方面的差異如何決定產品需求和商業化路線圖。分銷通路細分凸顯了線上零售和實體藥局零售之間的兩極化。線上管道分為電商平台和製造商網站，支援直接與消費者互動和訂閱模式。而實體藥局零售則分為強調面對面諮詢和現場衝動消費的連鎖藥局和獨立藥局。這些通路差異會影響包裝、隱私保護措施以及複檢和確認測試服務。

區域比較分析重點在於主要全球區域的法規結構、分銷網路和文化期望如何影響產品擴散和商業化。

區域趨勢在監管立場、報銷方式、供應鏈結構和終端用戶偏好存在顯著差異，所有這些因素共同影響市場參與企業的策略重點。在美洲，通常採用消費者付費分銷和雇主及臨床專案機構採購相結合的方式，並由完善的確認檢測實驗室網路和強大的藥房零售網路提供支援。對資料隱私的擔憂以及各州之間細微的監管差異，使得情境化標籤和本地化合規策略成為必要。

深入了解競爭定位、夥伴關係、製造策略和數位整合等關鍵因素，這些因素將決定一家公司在不斷發展的家庭藥物檢測生態系統中的成功。

家庭藥物檢測領域的競爭趨勢以產品創新、策略夥伴關係以及數位醫療公司日益重要的角色為特徵。成熟的診斷試劑製造商持續投資於改進檢測方法和拓展檢測參數，而敏捷的新興參與企業則採取以用戶為中心的設計、數位整合以及隱私和便利性為核心的打入市場策略。檢測開發商與遠端保健平台之間的合作日益普遍，使得基於檢測結果的臨床分流和通報成為可能，從而加強了篩檢與治療的整合。

為製造商和經銷商提供切實可行的建議，以提高產品可靠性、供應鏈韌性、合規性和跨通路商業化。

產業領導企業可以透過調整產品開發、供應鏈策略和分銷管道，使其與不斷變化的臨床和消費者期望相契合，從而獲得永續的競爭優勢。優先考慮分析的穩健性和第三方檢驗，以建立臨床醫生的信任；同時，增強易用性功能，以減少使用者錯誤並支援非監控測試情境。投資於數位顯示方案和安全資料傳輸，以確保結果能夠無縫整合到遠端保健管道和確認性測試工作流程中。

我們透明的調查方法，結合了對關鍵相關人員的訪談、二手技術審查、供應鏈分析和專家檢驗，確保了令人信服且可操作的見解。

本研究途徑整合了第一手和第二手調查方法，以確保對技術性能、分銷管道趨勢和相關人員需求有全面而深入的了解。第一手研究包括對醫療機構和診所的臨床負責人、採購經理、連鎖藥局和獨立藥局的決策者以及負責確認性檢測的實驗室經理進行結構化訪談。這些訪談提供了關於實際應用案例、採購標準和首選整合管道的定性背景資訊。

能夠突顯分析性能、易用性、供應鏈韌性和監管合規性策略交匯點的權威、綜合分析，將決定該領域未來的成功。

總之，居家藥物濫用檢測處於消費者健康、職業安全和臨床篩檢的策略性交會點，既需要嚴謹的分析方法，也需要以使用者為中心的設計。側向流動檢測、免疫檢測和數位讀數技術的進步正在擴大檢測的覆蓋範圍，同時圖與層析法確證試驗的必要整合。關稅導致的供應鏈中斷正在加速供應商多元化和本地化生產，這進一步凸顯了營運韌性的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：家庭藥物濫用檢測市場：依分銷管道分類

  • 線上
    • EC平台
    • 製造商網站
  • 藥局零售
    • 連鎖藥局
    • 獨立經營藥房

第9章：家庭藥物濫用檢測市場：依檢測類型分類

  • 多重藥物檢測
    • 5種類型的面板
    • 10種面板
    • 3種類型的面板
  • 單藥
    • 安非他命
    • 古柯鹼
    • 大麻
    • 鴉片類藥物

第10章：家庭藥物濫用檢測市場：依檢體類型分類

  • 頭髮
  • 唾液
    • 口腔液浸漬卡
    • 唾液拭子
  • 汗
  • 尿

第11章：家庭藥物濫用檢測市場：依技術分類

  • 層析法
    • 氣相層析法聯用
    • 液相層析法聯用
  • 免疫檢測
    • 競爭法
    • 三明治法
  • 側向流
    • 傳統的
    • 數位的

第12章：家庭藥物濫用檢測市場：依最終用戶分類

  • 診所
    • 職場計劃
    • 藥物濫用治療診所
  • 個人
  • 藥局
    • 鏈
    • 獨立經營

第13章：家庭藥物濫用檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：家庭藥物濫用檢測市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：家庭藥物濫用檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國家庭藥物濫用檢測市場

第17章：中國家用藥物濫用檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AccuQuik Test Kits
  • ACON Laboratories Inc.
  • Alere Inc.
  • American Screening Corporation
  • Bio-Rad Laboratories Inc.
  • Chembio Diagnostic Systems Inc.
  • Confirm Biosciences Inc.
  • First Check Diagnostics LLC
  • Laboratory Corporation of America Holdings
  • Medtox Laboratories Inc.
  • OraSure Technologies Inc.
  • PDC Healthcare
  • Premier BIoTech Inc.
  • Psychemedics Corporation
  • Quest Diagnostics Incorporated
  • Redwood Toxicology Laboratory Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
Product Code: MRR-B168537784E8

The At-home Drug of Abuse Testing Market was valued at USD 3.10 billion in 2025 and is projected to grow to USD 3.33 billion in 2026, with a CAGR of 7.40%, reaching USD 5.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.10 billion
Estimated Year [2026] USD 3.33 billion
Forecast Year [2032] USD 5.11 billion
CAGR (%) 7.40%

A concise introduction explaining how consumer demand, clinical needs, and technological advances are redefining at-home drug of abuse testing standards and expectations

The landscape for at-home drug of abuse testing has evolved from a niche consumer convenience into a strategic component of public health, occupational safety, and clinical pathways. Consumers now expect rapid, reliable testing options that balance privacy with clinical-grade accuracy, while clinicians and employers seek solutions that integrate confirmatory workflows and regulatory compliance. Advances in assay design, digital connectivity, and decentralized care models have converged to expand the context in which these tests are used, from point-of-care screening to remote monitoring and telehealth-facilitated interventions.

As testing technologies have diversified, stakeholder expectations have shifted toward transparency in analytical performance, chain-of-custody integrity where required, and clear pathways for confirmatory testing using laboratory-grade methods. Meanwhile, end users increasingly evaluate tests not only on sensitivity and specificity but also on usability, time-to-result, and data privacy considerations. Taken together, these dynamics have made the at-home drug testing category both more accessible and more complex, prompting manufacturers, payers, and regulators to rethink product design, distribution, and post-market surveillance approaches.

Moving forward, successful entrants will need to demonstrate robust clinical validation, interoperable data ecosystems, and supply chain resilience. These elements will determine which products gain acceptance across clinical programs, employer testing frameworks, and consumer channels, thereby shaping long-term adoption patterns and quality expectations in the sector.

A detailed exploration of the structural and technological shifts transforming how at-home drug testing is validated, delivered, and connected to clinical pathways

Major transformative shifts are reshaping the at-home drug testing landscape, driven by a combination of technological breakthroughs, regulatory pragmatism, and shifting stakeholder priorities. Point-of-care immunoassays and lateral flow devices have improved user experience through simplified workflows and faster results, while digital lateral flow variants now enable automated reading and secure data transmission, reducing user interpretation error and facilitating remote confirmation workflows. At the same time, chromatography-based confirmatory testing remains the analytical gold standard, reinforcing hybrid pathways that combine at-home screening with laboratory confirmation.

In parallel, telehealth expansion and increased attention to behavioral health have created pathways for test results to trigger timely clinical interventions and substance use treatment referrals. Regulatory bodies have increasingly focused on ensuring that at-home devices meet minimum performance thresholds and clear labeling expectations, fostering greater trust among clinicians and consumers. Supply chain visibility and component traceability have also gained prominence, encouraging manufacturers to diversify suppliers and explore nearshoring for critical reagents and strip components.

Consequently, competitive advantage is now defined not only by analytical performance but also by the ability to integrate digitally, maintain compliance across jurisdictions, and offer seamless confirmatory and care pathways. These shifts point to an industry moving toward higher quality, safer distribution, and closer ties between screening and clinical decision-making.

An analytical assessment of how cumulative tariff measures enacted by 2025 are reshaping sourcing, manufacturing, pricing, and distribution strategies across the global at-home testing value chain

Cumulative tariff actions implemented through 2025 have introduced new cost and sourcing dynamics that affect manufacturers, distributors, and retail channels across the at-home drug testing space. Increased import duties on certain components and finished goods have pressured gross margins, prompting manufacturers to reassess supplier portfolios and consider alternatives that reduce exposure to tariff volatility. As a result, many firms have prioritized supplier diversification, exploring component sourcing from countries outside tariff-impacted trade lanes and negotiating longer-term contracts to stabilize input pricing.

In response to higher landed costs, some manufacturers have accelerated investments in domestic manufacturing capabilities or contract manufacturing partnerships within lower-tariff jurisdictions to preserve competitiveness. At the distribution level, retailers and online platforms have adjusted pricing, promotional cadence, and inventory strategies to manage consumer affordability while protecting retail margins. These adjustments have amplified the importance of operational efficiencies, such as leaner packaging, consolidated shipping, and demand-driven production runs, to offset incremental tariff-related costs.

Moreover, tariffs have influenced strategic decisions around product design, encouraging modularization of kits so that higher-tariff components can be localized. The net effect is a more resilient supply chain architecture that emphasizes near-term cost mitigation while building capacity for localized production, which in turn supports regulatory traceability and shorter lead times for both pharmacies and direct-to-consumer channels.

In-depth segmentation analysis that connects distribution channels, test formats, specimen types, analytical methods, and end-user requirements to commercialization imperatives and product design choices

Key segmentation insights reveal how variations across channels, test formats, specimen types, analytical technologies, and end users define product requirements and commercialization pathways. Distribution channel segmentation highlights the dual trajectory of online and pharmacy retail; online is bifurcated into e-commerce platforms and manufacturer websites, enabling direct-to-consumer engagement and subscription models, while pharmacy retail divides into chain and independent pharmacies that emphasize in-person counseling and impulse aisle presence. These channel distinctions influence packaging, privacy features, and return or confirmatory testing services.

Test type segmentation differentiates between multi-drug panel and single-drug formats. Multi-drug panels include commonly deployed configurations such as three-panel, five-panel, and ten-panel devices that target screening breadth for workplace and clinical settings, whereas single-drug tests focus on analyte-specific detection for substances including amphetamines, cocaine, marijuana, and opiates. This distinction affects assay complexity, regulatory pathways, and marketing claims.

Sample type segmentation encompasses urine, hair, saliva, and sweat collection modalities. Saliva itself is further specified into oral fluid dip cards and saliva swabs, each with trade-offs in collection ease, detection windows, and suitability for observed versus unobserved testing. Technology segmentation spans chromatography, immunoassay, and lateral flow techniques. Chromatography subdivides into gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry for laboratory confirmation; immunoassay differentiates competitive and sandwich formats that influence sensitivity and cross-reactivity profiles; lateral flow separates conventional visual-read strips from digital readers that enhance objectivity and connectivity. End user segmentation captures clinics, individuals, and pharmacies, with clinics further categorized into occupational programs and substance abuse clinics and pharmacies differentiated between chain and independent operators. Each end-user group prioritizes different product attributes-from chain pharmacies' focus on standardized stocking and throughput to occupational programs' emphasis on documented chain of custody-shaping product design, service bundles, and distribution strategies.

A comparative regional analysis highlighting how regulatory frameworks, distribution networks, and cultural expectations shape adoption and commercialization in major global regions

Regional dynamics differ materially in regulatory posture, reimbursement approaches, supply chain structure, and end-user preferences, which together shape strategic priorities for market entrants. The Americas typically show a mix of private-pay consumer adoption alongside institutional procurement by employers and clinical programs, with established confirmatory lab networks and a strong pharmacy retail footprint supporting broad distribution. In this region, data privacy concerns and state-level regulatory nuances require adaptive labeling and localized compliance strategies.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory frameworks vary from tightly regulated markets with centralized approvals to regions where informal procurement channels persist. In these markets, partnerships with regional distributors and alignment with local clinical laboratory networks are essential for establishing trust and ensuring pathways for confirmatory testing. Additionally, cultural considerations and public health priorities influence adoption patterns, particularly in workplace testing and clinical screening programs.

Asia-Pacific encompasses diverse economies with rapidly growing digital health adoption and varied manufacturing capabilities. Several markets in this region prioritize domestic production and local regulatory approvals, creating opportunities for co-development and contract manufacturing. Cross-border trade dynamics and regional supply chains also play a pivotal role in sourcing components and scaling distribution. Across all regions, successful strategies blend regulatory agility, localized go-to-market models, and distribution partnerships that reflect the specific payer mix and healthcare infrastructure.

Critical insights into competitive positioning, partnerships, manufacturing strategies, and digital integration that define company success in the evolving at-home drug testing ecosystem

Competitive dynamics in the at-home drug testing sector are characterized by product innovation, strategic partnerships, and a growing role for digital health firms. Established diagnostic manufacturers continue to invest in assay refinement and expanded test menus, while agile entrants pursue user-centered design, digital integration, and go-to-market strategies that emphasize privacy and convenience. Collaboration between assay developers and telehealth platforms is increasingly common, enabling results to prompt clinical triage or referrals and strengthening the linkage between screening and care.

Supply chain partners, including contract manufacturers and specialist reagent suppliers, have assumed greater strategic importance as companies balance cost pressures with quality and compliance demands. Similarly, retail and e-commerce partners shape distribution reach and customer acquisition strategies, with chain pharmacies offering scale and independents delivering localized patient counseling. Lab services providers maintain a central role in confirmation testing, creating ongoing demand for high-fidelity chromatography confirmatory workflows.

Mergers, licensing deals, and co-development agreements are frequently used to accelerate market entry and fill capability gaps, such as digital readout integration or scalable manufacturing. Overall, competitive success depends on the ability to combine validated analytical performance with dependable supply chains, digital interoperability, and clear clinician and consumer value propositions.

Actionable recommendations for manufacturers and distributors to strengthen product credibility, supply chain resilience, regulatory alignment, and channel-specific commercialization

Industry leaders can capture sustainable advantage by aligning product development, supply chain strategy, and distribution with emerging clinical and consumer expectations. Prioritize analytic robustness and third-party validation to build clinician trust while simultaneously enhancing usability features that reduce user error and support unobserved testing scenarios. Invest in digital readout options and secure data transmission so that results can feed telehealth pathways and confirmatory testing workflows with minimal friction.

On the supply chain front, diversify suppliers and evaluate nearshoring or local contract manufacturing to mitigate tariff-driven cost volatility and compress lead times. Negotiate multi-year supply agreements for critical reagents and consider modular kit designs to enable flexible sourcing. For channel strategy, tailor offerings to the needs of pharmacy retail-where in-person counseling and shelf presence matter-and to online channels that prioritize privacy, subscription models, and direct-to-consumer support. Finally, engage proactively with regulators and clinical stakeholders to shape guidance, streamline approvals, and ensure that labeling communicates appropriate performance characteristics and next-step actions for positive screens.

Executing these recommendations will require cross-functional coordination among R&D, regulatory, commercial, and supply chain teams, as well as clear metrics for usability, analytical performance, and post-market surveillance to measure impact and enable iterative improvement.

A transparent research methodology combining primary stakeholder interviews, secondary technical review, supply chain analysis, and expert validation to ensure defensible and actionable insights

The research approach integrates primary and secondary methods to ensure a robust, triangulated understanding of technology performance, channel dynamics, and stakeholder needs. Primary research includes structured interviews with clinical leaders, procurement executives at employers and clinics, chain and independent pharmacy decision makers, and laboratory directors responsible for confirmatory testing. These conversations provide qualitative context on real-world use cases, procurement criteria, and preferred integration pathways.

Secondary research synthesizes scientific literature, regulatory filings, product instructions for use, and manufacturer documentation to evaluate analytical principles across chromatography, immunoassay, and lateral flow technologies. Supply chain mapping and tariff impact assessments draw on customs records, trade data, and industry reporting to analyze sourcing footprints and cost drivers. Product performance claims are cross-checked against peer-reviewed validation studies and post-market surveillance reports where available. Data triangulation and expert review processes are applied throughout to reconcile differing sources and arrive at defensible insight, while methodological limitations and assumptions are transparently documented to support client interpretation.

A conclusive synthesis highlighting the strategic intersection of analytical performance, usability, supply chain resilience, and regulatory alignment that will determine future success in the category

In conclusion, at-home drug of abuse testing occupies a strategic intersection of consumer healthcare, occupational safety, and clinical screening that demands both analytical rigor and user-centric design. Technological progress in lateral flow, immunoassay formats, and digital readouts has expanded access while preserving necessary links to chromatography-based confirmatory testing. Tariff-driven supply chain disruption has accelerated supplier diversification and localized manufacturing initiatives, reinforcing the need for operational resilience.

Segmentation analysis shows that distribution channels, test formats, specimen types, analytical technologies, and end-user requirements each drive distinct product specifications and go-to-market strategies. Regional variance in regulation, payer mix, and healthcare infrastructure further necessitates bespoke commercial approaches. Companies that succeed will be those that integrate clinical validation, digital interoperability, supply chain agility, and clear post-test care pathways into cohesive value propositions. As stakeholders continue to prioritize both accuracy and accessibility, the market will reward offerings that combine validated performance with seamless connectivity to care and compliance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. At-home Drug of Abuse Testing Market, by Distribution Channel

  • 8.1. Online
    • 8.1.1. Ecommerce Platforms
    • 8.1.2. Manufacturer Websites
  • 8.2. Pharmacy Retail
    • 8.2.1. Chain Pharmacy
    • 8.2.2. Independent Pharmacy

9. At-home Drug of Abuse Testing Market, by Test Type

  • 9.1. Multi-Drug Panel
    • 9.1.1. Five Panel
    • 9.1.2. Ten Panel
    • 9.1.3. Three Panel
  • 9.2. Single Drug
    • 9.2.1. Amphetamines
    • 9.2.2. Cocaine
    • 9.2.3. Marijuana
    • 9.2.4. Opiates

10. At-home Drug of Abuse Testing Market, by Sample Type

  • 10.1. Hair
  • 10.2. Saliva
    • 10.2.1. Oral Fluid Dip Card
    • 10.2.2. Saliva Swab
  • 10.3. Sweat
  • 10.4. Urine

11. At-home Drug of Abuse Testing Market, by Technology

  • 11.1. Chromatography
    • 11.1.1. Gas Chromatography-Mass Spectrometry
    • 11.1.2. Liquid Chromatography-Mass Spectrometry
  • 11.2. Immunoassay
    • 11.2.1. Competitive
    • 11.2.2. Sandwich
  • 11.3. Lateral Flow
    • 11.3.1. Conventional
    • 11.3.2. Digital

12. At-home Drug of Abuse Testing Market, by End User

  • 12.1. Clinics
    • 12.1.1. Occupational Programs
    • 12.1.2. Substance Abuse Clinics
  • 12.2. Individuals
  • 12.3. Pharmacies
    • 12.3.1. Chain
    • 12.3.2. Independent

13. At-home Drug of Abuse Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. At-home Drug of Abuse Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. At-home Drug of Abuse Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States At-home Drug of Abuse Testing Market

17. China At-home Drug of Abuse Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AccuQuik Test Kits
  • 18.7. ACON Laboratories Inc.
  • 18.8. Alere Inc.
  • 18.9. American Screening Corporation
  • 18.10. Bio-Rad Laboratories Inc.
  • 18.11. Chembio Diagnostic Systems Inc.
  • 18.12. Confirm Biosciences Inc.
  • 18.13. First Check Diagnostics LLC
  • 18.14. Laboratory Corporation of America Holdings
  • 18.15. Medtox Laboratories Inc.
  • 18.16. OraSure Technologies Inc.
  • 18.17. PDC Healthcare
  • 18.18. Premier Biotech Inc.
  • 18.19. Psychemedics Corporation
  • 18.20. Quest Diagnostics Incorporated
  • 18.21. Redwood Toxicology Laboratory Inc.
  • 18.22. Siemens Healthineers
  • 18.23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ECOMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ECOMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ECOMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY THREE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY THREE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY THREE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MARIJUANA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MARIJUANA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MARIJUANA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY OPIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY OPIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY OPIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID DIP CARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID DIP CARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID DIP CARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SWEAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SWEAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SWEAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COMPETITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COMPETITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COMPETITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SANDWICH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SANDWICH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SANDWICH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY OCCUPATIONAL PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY OCCUPATIONAL PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY OCCUPATIONAL PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SUBSTANCE ABUSE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SUBSTANCE ABUSE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SUBSTANCE ABUSE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDIVIDUALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDIVIDUALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDIVIDUALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 274. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 277. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 278. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 280. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 281. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 283. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 287. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY PHARMACY RETAIL, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY MULTI-DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SINGLE DRUG, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION AT-HOME DRUG OF ABUSE TESTING MARKET